Nomura Holdings Inc. Makes New $1.11 Million Investment in ResMed Inc. (NYSE:RMD)

Nomura Holdings Inc. purchased a new stake in ResMed Inc. (NYSE:RMD) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 4,841 shares of the medical equipment provider’s stock, valued at approximately $1,107,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Park Avenue Securities LLC boosted its stake in ResMed by 101.1% in the 4th quarter. Park Avenue Securities LLC now owns 4,431 shares of the medical equipment provider’s stock worth $1,013,000 after purchasing an additional 2,228 shares during the period. Merit Financial Group LLC bought a new stake in shares of ResMed in the fourth quarter valued at about $460,000. Brooklyn Investment Group boosted its position in shares of ResMed by 8.1% during the fourth quarter. Brooklyn Investment Group now owns 911 shares of the medical equipment provider’s stock worth $208,000 after buying an additional 68 shares during the period. Aaron Wealth Advisors LLC grew its holdings in shares of ResMed by 25.2% during the fourth quarter. Aaron Wealth Advisors LLC now owns 1,607 shares of the medical equipment provider’s stock worth $368,000 after buying an additional 323 shares in the last quarter. Finally, LVW Advisors LLC raised its position in ResMed by 23.4% in the 4th quarter. LVW Advisors LLC now owns 3,098 shares of the medical equipment provider’s stock valued at $708,000 after buying an additional 587 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Stock Performance

NYSE:RMD opened at $251.75 on Monday. The company has a market cap of $36.91 billion, a price-to-earnings ratio of 29.72, a PEG ratio of 1.53 and a beta of 0.78. ResMed Inc. has a fifty-two week low of $179.42 and a fifty-two week high of $263.05. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The stock has a fifty day moving average price of $225.34 and a 200-day moving average price of $234.11.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.01. ResMed had a net margin of 25.34% and a return on equity of 26.17%. The business had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter in the prior year, the business posted $2.13 earnings per share. ResMed’s revenue was up 7.9% compared to the same quarter last year. As a group, equities analysts anticipate that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date of this dividend is Thursday, May 8th. ResMed’s dividend payout ratio (DPR) is presently 23.79%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on RMD shares. Morgan Stanley began coverage on shares of ResMed in a research note on Wednesday, March 19th. They set an “overweight” rating and a $280.00 price target for the company. UBS Group decreased their target price on shares of ResMed from $290.00 to $285.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. KeyCorp set a $274.00 price target on shares of ResMed in a research note on Thursday, April 24th. JPMorgan Chase & Co. increased their price objective on shares of ResMed from $286.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, April 24th. Finally, Piper Sandler decreased their price objective on ResMed from $260.00 to $248.00 and set a “neutral” rating for the company in a report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, ResMed has an average rating of “Moderate Buy” and a consensus target price of $258.83.

Insider Buying and Selling

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $227.71, for a total transaction of $455,420.00. Following the completion of the transaction, the director now directly owns 75,218 shares in the company, valued at $17,127,890.78. The trade was a 2.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Kaushik Ghoshal sold 9,113 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $235.40, for a total value of $2,145,200.20. Following the completion of the sale, the insider now directly owns 9,725 shares in the company, valued at approximately $2,289,265. This represents a 48.38% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,949 shares of company stock worth $11,335,320. Corporate insiders own 0.71% of the company’s stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.